E-Therapeutics PLC

LSE:ETX

e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. The company is headquartered in Witney, Oxfordshire and currently employs 18 full-time employees. The company went IPO on 2007-11-28. The firm's platform is a combination of databases and a suite of computational tools that employ network analysis, data mining, machine learning, artificial intelligence (Al) and optimization. Its in silico platform serves as a laboratory, which enables it to computationally test potential therapeutic interventions. Its network-driven drug discovery (NDD) technology performs computational phenotypic screens to identify efficacious drugs. Its genome-associated interactions networks (GAINs) technology interprets genomic data in the context of the biological networks, in which the genes function. Its ribonucleic acid (RNA) Interference, (RNAi) platform is in development to complement its computational toolset. The firm identifies new therapeutic approaches to modulate a specific mechanism involved in Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic indications through Galapagos NV (Galapagos).